Seroatlas · Human Serome Atlas

AMZ2

Archaemetzincin-2

Also known as: AMZ2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q86W34
Gene: AMZ2
Ensembl: ENSG00000196704
Chromosome: 17
Canonical length: 360 aa
Protein class: Enzymes, Predicted intracellular proteins
Subcellular location: Nucleoplasm,Nuclear bodies,Cytosol

OverviewNCBI Gene

The protein encoded by this gene is a zinc metalloprotease that displays some activity against angiotensin-3. The encoded protein is inhibited by the aminopeptidase inhibitor amastatin, as well as by the general inhibitors o-phenanthroline and batimastat. Defects in this gene may be associated with lung tumorigenesis. [provided by RefSeq, Oct 2016]

Canonical amino-acid sequenceUniProt

360 residues, UniProt reviewed canonical sequence.

>Q86W34|AMZ2
     1  MQIIRHSEQT LKTALISKNP VLVSQYEKLN AGEQRLMNEA FQPASDLFGP ITLHSPSDWI
    61  TSHPEAPQDF EQFFSDPYRK TPSPNKRSIY IQSIGSLGNT RIISEEYIKW LTGYCKAYFY
   121  GLRVKLLEPV PVSVTRCSFR VNENTHNLQI HAGDILKFLK KKKPEDAFCV VGITMIDLYP
   181  RDSWNFVFGQ ASLTDGVGIF SFARYGSDFY SMHYKGKVKK LKKTSSSDYS IFDNYYIPEI
   241  TSVLLLRSCK TLTHEIGHIF GLRHCQWLAC LMQGSNHLEE ADRRPLNLCP ICLHKLQCAV
   301  GFSIVERYKA LVRWIDDESS DTPGATPEHS HEDNGNLPKP VEAFKEWKEW IIKCLAVLQK

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against AMZ2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Unknown
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.26
Highest tissue expression: 183 nTPM

Expression across tissuesHPA

Tissue

testis: 183 nTPM
skeletal muscle: 90 nTPM
tongue: 81 nTPM
cerebral cortex: 79 nTPM
basal ganglia: 78 nTPM
heart muscle: 72 nTPM

Single-cell type

late spermatids: 2,072 nCPM
late primary spermatocytes: 551 nCPM
early spermatids: 499 nCPM
astrocytes: 472 nCPM
ependymal cells: 390 nCPM
choroid plexus epithelial cells: 278 nCPM

Immune cell

basophil: 77 nTPM
NK-cell: 64 nTPM
T-reg: 59 nTPM
MAIT T-cell: 47 nTPM
memory CD8 T-cell: 46 nTPM
neutrophil: 46 nTPM

Brain region

cerebral cortex: 97 nTPM
basal ganglia: 78 nTPM
white matter: 67 nTPM
medulla oblongata: 65 nTPM
hippocampal formation: 64 nTPM
thalamus: 64 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.45
gnomAD pLI: 0
gnomAD missense Z: 0.22
DepMap mean gene effect: 0
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 10% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

proteolysis

Molecular functions

Protein domainsUniProt · Pfam · InterPro

Peptidase M54, archaemetzincin
Metallopeptidase, catalytic domain superfamily
Archaemetzincin
Peptidase family M54

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads AMZ2 as an antibody target. Whether an autoantibody or antibody against AMZ2 could matter depends on whether native AMZ2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

AMZ2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label AMZ2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...